AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00010803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgo biloba
Description: 120mg twice a day
Study NCT00010803 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One pill twice daily
Study NCT01415908 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INFUSE Bone Graft
Description: Subjects enrolled in the investigational treatment group will receive surgical treatment with INFUSE® Bone Graft, the CAPSTONE® Spinal System, and posterior supplemental fixation (in this study the CD HORIZON® Spinal System). The investigational treatment will be implanted using a TLIF surgical approach.
Study NCT01415908 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Iliac Crest Bone Graft
Description: Subjects enrolled in the control group will receive the same surgical treatment as the investigational group, including the CAPSTONE® Spinal System and posterior supplemental fixation system (CD HORIZON® Spinal System), except for the use of autogenous bone graft (from the iliac crest) instead of INFUSE® Bone Graft. A TLIF surgical approach will also be used for implanting the control treatment.
Study NCT00650312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride ER Tablets 500 mg
Description: 500mg, single dose fasting
Study NCT00650312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage® XR Tablets 500 mg
Description: 500mg, single dose fasting
Study NCT04456595 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adsorbed COVID-19 (inactivated) Vaccine
Description: Adsorbed COVID-19 (inactivated) Vaccine manufactured by Sinovac
Study NCT04456595 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of Adsorbed COVID-19 (inactivated) Vaccine manufactured by Sinovac
Study NCT02485613 — intervention group
Intervention type: DRUG
Intervention: bortezominb and dexamethasone
Description: The initial BD regimen included bortezomib (1.3 mg/m2 i.v.) and dexamethasone (40 mg i.v.) twice weekly for 2 weeks (days 1, 4, 8, and 11), which was followed by a 10-day rest period (days 12-21). The dose of bortezomib and dexamethasone can be adjusted according to the patients' condition.
Study NCT04111653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mud therapy
Description: Application of sludge poultice
Study NCT04208880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TBH Brain Workout 1.0
Description: TBH Brain Workout program with easy challenge activities.
Study NCT04208880 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain Health Book Club
Description: Each week a new chapter will be read that contains new information to enhance brain health.
Study NCT04208880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TBH Brain Workout 2.0
Description: TBH Brain Workout program with moderately difficult challenge activities.
Study NCT04208880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TBH Memory 1.0
Description: TBH Memory program with easy challenge activities.
Study NCT04208880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TBH Memory 2.0
Description: TBH Memory program with moderately difficult challenge activities
Study NCT02794025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: patients in the esmolol group received continuous infusion of esmolol via a micro-pump through a catheter placed in the superior vena cava. The initial dose was 0.05 mg/kg/min and was adjusted based on heart rate (HR) (target HR: 70 bpm \< HR \< 100 bpm within 72 hours).~Control group also received natural saline via a micro pump, in the same way the esmolol group received esmolol.
Study NCT02794025 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: natural saline
Description: Control group also received natural saline via a micro pump,
Study NCT01733836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT01733836 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03022513 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gluten free diet
Description: The investigators will evaluate the prevalence of fibromyalgia-like joint/muscle pain and the possible ultrasonographical alterations (i.e. synovitis) of hands and feet joints in NCWS patient at baseline (i.e. at the moment of diagnosis) and after a gluten free diet period of almost 6 months.
Study NCT02537223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Study NCT02537223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT02537223 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy (IMRT)
Study NCT02844673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea
Description: Patients will receive fixed dose Hydroxyurea therapy (15 mg/Kg/day) with standard monitoring
Study NCT02844673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Patients will receive fixed dose Hydroxyurea therapy (15 mg/Kg/day) with standard monitoring
Study NCT02844673 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile Directly Observed Therapy
Description: Mobile DOT will consist of a web based medication adherence monitoring system that includes direct video confirmation of adherence using the patient's personal cellular telephone. Patients will receive alerts on their cell phone at pre-arranged times to remind them to take their medications.
Study NCT02244229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Study NCT02244229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finasteride
Study NCT02244229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT02244229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03771495 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Joint Mobilization
Description: Manual Therapy Intervention, commonly used by physiotherapists
Study NCT03771495 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Laying on of Hands
Description: Sham Hip Joint Mobilization
Study NCT00778310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate-OROS
Description: The collaborator (Ortho-McNiel Janssen Scientific Affairs, LLC) will provide capsules of Concerta that are made to appear similar to placebo capsules. The subject will be administered their usual dose of Concerta the morning of the scan.
Study NCT00778310 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The collaborator (Ortho-McNiel Janssen Scientific Affairs, LLC) will provide capsules of placebo that are made to appear similar to Concerta capsules. The subject will be administered placebo the morning of the scan.
Study NCT02597192 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: probiotic oral hygiene products with Bacillus (PIP, Chrisal)
Description: products with Bacillus probiotics
Study NCT02597192 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: oral hygiene products without Bacillus
Description: products without Bacillus
Study NCT00643448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1305
Description: AZD1305 loading dose 250 mg + 125 mg evening dose on Study Day 1, maintenance dose 125 mg twice daily from Study Day 2
Study NCT00643448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1305
Description: AZD1305 loading dose 500 mg + placebo evening dose on Study Day 1, maintenance dose 125 mg twice daily from Study Day 2
Study NCT00643448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo corresponding to AZD1305 loading dose + evening dose on Study Day 1, maintenance dose twice daily from Study Day 2
Study NCT02176980 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief alcohol counseling
Description: Medical provider gives feedback on how the patient's alcohol use may affect their current and future health, noting that it is the patient's responsibility to change behavior; giving advice to stop drinking based on medical concern; giving a menu of options for cutting down on drinking; expressing empathy; and reinforcing the patient's self-efficacy to change.
Study NCT02176980 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group and Individual Therapy Sessions
Description: Session content integrates HCV and alcohol issues in treatment, liver health, and personal realms. Sessions include psychoeducational content on how alcohol affects the liver among people with HCV; HCV stigma; family issues around drinking and the HCV diagnosis; nutrition; life goals and positive affect; and alcohol reduction strategies.
Study NCT03127436 — intervention group
Intervention type: DRUG
Intervention: Acarovac
Description: House dust mite sensitized Patients receive increasing doses of subcutaneous immunotherapy with Acarovac. During the up-dosing phase, patients will receive 4 injections in 1-2 week intervals with increasing allergen amount up to the individual maximum tolerable dose. After reaching the individual maximum tolerable dose patients will receive one maintenance dose in a 4 - 8 week interval.
Study NCT02786836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13C-Methacetin
Description: The test substrate in this study, ¹³C-methacetin solution for single-use oral administration (75 mg in 150 ml purified water), is administered orally or via feeding tube, rapidly absorbed, exclusively metabolized by hepatic mixed function oxidase via O-demethylation, mainly by cytochrome P450 enzyme, subtype 1A2, into acetaminophen and formaldehyde. The formaldehyde is then transformed through two successive oxidative steps to ¹³carbon dioxide, the quantity of which is measured in exhaled breath as a ratio of 13C to 12C.~The nasal or intubated breath sampling investigational device (ID) circuit continuously transports the breath sample from the patient to the BreathID® MCS device before and following administration of the 13C-methylacetanilide test substrate.
Study NCT01802515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine, low dose
Description: The effects of 40mg low dose atomoxetine will be compared to placebo and to the 80mg atomoxetine high dose.
Study NCT01802515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine, high dose
Description: The effects of 80mg of high dose atomoxetine will be compared to placebo and to 40mg atomoxetine low dose.
Study NCT01802515 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The effects of placebo will be compared to the parallel groups of Atomoxetine high (80mg) dose and Atomoxetine low (40mg) dose.
Study NCT01002495 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VM202
Description: Endocardial injections on Day 0.
Study NCT00154193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine
Description: patients will receive maintenance triple immunosuppression according to local practice consisting of Sandimmun Neoral, MMF/ECMPA or azathioprin and steroids.
Study NCT04909294 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiotherapy with Linac MRI
Description: 38 Gy in 4 fractions of 9.5 Gy over the entire prostate,~+/- 2 Gy in 4 fractions of 0.5 Gy as an integrated boost on the index tumor if it is visible on diagnostic multiparametric MRI (PIRADS-V2 score 4 or 5) and on planning MRI performed on Linac MRI.
Study NCT01292525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: A control group continued conventional therapy, Tacrolimus (Prograf®) (control group) and will be followed in parallel group withdrawal that will stop treatment with Tacrolimus (Prograf®).
Study NCT01292525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients randomized to the withdrawalgroup will begin the protocol with their usual dose of Tacrolimus (Prograf®) (initial dose). The initial dose of tacrolimus (Prograf®) will be reduced by one third at visit 3 (day 0) and again a third visit 5 (J60). The complete withdrawal Tacrolimus (Prograf®) begins to visit 7 (J120). The withdrawal of Tacrolimus (Prograf®) will be obtained in four months. Monitoring of all patients lasted 17 months in total from the screening visit, which corresponds to 12 months after complete withdrawal of Tacrolimus (Prograf®) for patients in the withdrawal group.
Study NCT02251067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VPI-2690B low dose
Description: Comparison of different doses of study drug
Study NCT02251067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VPI-2690B medium dose
Description: Comparison of different doses of study drug
Study NCT02251067 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match VPI-2690B
Study NCT02251067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VPI-2690B high dose
Description: Comparison of different doses of study drug
Study NCT01752075 — intervention group
Intervention type: DRUG
Intervention: Revlimid
Description: The prescribing physician should prescribe and monitor REVLIMID therapy according to the guidance and recommended schedules given in the approved Taiwan package insert (PI).
Study NCT04324268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lirentelimab (AK002)
Description: Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
Study NCT03582189 — intervention group
Intervention type: OTHER
Intervention: MRI
Description: Patients who consent to this study will have an abdominal MRI prior to or immediately after each fraction of radiation treatment in the case of those patients that are undergoing SBRT or those receiving palliative treatment. On patients receiving definitive chemoradiation, an abdominal MRI will be performed prior to or immediately after radiation treatment once per week during the any five weeks of treatment
Study NCT04324268 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03403855 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rocket® IPC- Long External Length
Description: Rocket® IPC- Long External Length Intervention. Evaluation of Long and Short External Length Rocket® Pleural Catheters in Terms of Quality of Life, Feasibility and Satisfaction in Patients Being Treated for Recurrent Malignant Pleural Effusions
Study NCT03403855 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rocket® IPC- Short External Length
Description: Rocket® IPC- Short External Length Intervention. Evaluation of Long and Short External Length Rocket® Pleural Catheters in Terms of Quality of Life, Feasibility and Satisfaction in Patients Being Treated for Recurrent Malignant Pleural Effusions
Study NCT04319640 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy for insomnia
Description: CBT-I for children with ASD includes sleep hygiene, restriction of time in bed, stimulus control, cognitive therapy, and relaxation techniques. The treatment consists of 5 weekly modules.
Study NCT04319640 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychoeducation for ASD
Description: psychoeducation contains information about ASD, The treatment consists of 5 weekly modules.
Study NCT04319640 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: psychoeducation for ASD
Description: psychoeducation contains information about ASD, The treatment consists of 5 weekly modules.
Study NCT03998891 — intervention group
Intervention type: OTHER
Intervention: restricted dietary salt intake
Description: These patients after CRTd will receive a restricted dietary salt intake. To date, the salt intake will be 1500 grams daily.
Study NCT02579902 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 (Cholecalciferol)
Description: 50000 IU Vitamin D3 (Cholecalciferol) will be given as one gelcaps every 2 weeks for a period of 6 months.
Study NCT02579902 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo will be given in identical gelcaps once every 2 weeks for a period of 6 months.
Study NCT01085656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OXi4503
Description: Two safety cohorts treating two (2) patients at a dose of 2.5 mg/m2 followed by two patients at 3.75 mg/m2 will be completed prior to beginning at the dose level of 5 mg/m2.~Dosing of OXi4503 will be an intravenous infusion (IV) over 10 minutes on Days 1, 8, 15, and 22 of each 28 day cycle.~Dose escalations and de-escalations of 25% will be made until the maximum tolerated dose is reached.~Number of cycles: After Cycle 1, subjects who achieve stable disease (SD) or greater response may continue to receive additional cycles of treatment until either disease progression (defined as greater than 25% increase in leukemia myeloblasts in the bone marrow compared to baseline examination) or unacceptable toxicity due to the investigational agent.
Study NCT03385525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB074
Description: Administered as specified in the treatment arm
Study NCT03385525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Administered as specified in the treatment arm
Study NCT02562027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30
Description: * 30 quality of life questions for the participant to answer~* The first 28 questions have answers that range from 1 (Not at All) to 4 (Very Much)~* The final 2 questions answers range from 1 (Very Poor) to 7 (Excellent)~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment
Study NCT02562027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire LC-13
Description: * 13 quality of life questions for the participant to answer~* The answers range from 1 (Not at All) to 4 (Very Much)~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment
Study NCT02562027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Medical Research Council
Description: * Participants is given 5 grades to choose from ranging from 0 to 4 and participant will choose grade~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment
Study NCT02562027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EQ-5D
Description: * 5 headings with 5 statements and the participant will check the box that best describes how he or she feels that day~* The second part shows a scale ranging from 0 (worst health) to 100 (best health) and the participant chooses the best number on the scale~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment
Study NCT02562027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Center for Epidemiological Studies Depression Scale
Description: * 20 quality of life questions for the participant to answer~* Answers range from Rarely or none of the time to Most or all of the time~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment
Study NCT02562027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical Outcomes Study Social Support Survey
Description: * 19 quality of life questions for the participant to answer~* Answers from from 1 (None of the time) to 5 (All of the time)~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment
Study NCT00323310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gadobenate dimeglumine
Description: A dose of 0.10 mmol/kg (i.e., 0.2 mL/kg) of 0.5 molar MultiHance was injected intravenously at a rate of 2 mL/sec as a single dose.
Study NCT02078661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PG101
Description: A topical gel containing either 1% or 0.25% PG101 active.
Study NCT02078661 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PG101
Description: A topical gel containing either 1% or 0.25% PG101 active.
Study NCT02896192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: Once daily SC injection
Study NCT02896192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Once daily SC injection
Study NCT02079519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab was provided as a concentrate in vials.
Study NCT00645515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: Initial dose of 40 mg capsules twice daily on Days 1-3; dose could be flexibly changed within the range of 40 to 80 mg twice daily for the remainder of the study; treatment duration was 24 weeks.
Study NCT00645515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Initial dose of 10 mg once daily on Days 1-3; dose could be flexibly changed within the range of 3 to 9 mg twice daily for the remainder of the study; treatment duration was 24 weeks.
Study NCT00062647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telavancin
Description: Telavancin 10mg/kg/day IV every 24 hrs for up to 14 days